1 Min Read
Dec 26 (Reuters) - Alexion Pharmaceuticals Inc:
* SOLIRIS® (ECULIZUMAB) RECEIVES MARKETING AUTHORIZATION IN JAPAN FOR THE TREATMENT OF PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (GMG) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.